Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 11INDUSTRY 8NIH 3

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2

Conditions

Neoplasms 51Multiple Myeloma 42Lymphoma 42Neoplasm Metastasis 41Lung Neoplasms 38Breast Neoplasms 38Prostatic Neoplasms 32Carcinoma, Non-Small-Cell Lung 31Leukemia, Myeloid, Acute 30Colorectal Neoplasms 28Melanoma 27Ovarian Neoplasms 26Hematologic Neoplasms 24Pancreatic Neoplasms 22Urinary Bladder Neoplasms 21Lymphoma, Non-Hodgkin 21Glioma 21Carcinoma, Renal Cell 19Sarcoma 18Myelodysplastic Syndromes 16Burkitt Lymphoma 16Triple Negative Breast Neoplasms 15Stomach Neoplasms 15Neuroblastoma 14Colonic Neoplasms 14Brain Neoplasms 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Large B-Cell, Diffuse 13Leukemia, Lymphocytic, Chronic, B-Cell 13Fallopian Tube Neoplasms 13

Interventions

zanubrutinib 1venetoclax 1ibrutinib 1Specimen Handling 1Rituximab 1Magnetic Resonance Spectroscopy 1CT-P10 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Waldenstrom Macroglobulinemia × 30 days × Clear all
NCT00039676 2026-06-04

Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer

National Institutes of Health Clinical Center (CC)

Active not recruiting
1,836 enrolled
LymphoidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00923507 2026-06-04

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

National Institutes of Health Clinical Center (CC)

Recruiting
1,000 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Waldenstrom Macroglobulinemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT04840602 2026-06-03

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

National Cancer Institute (NCI)

Phase 2 Recruiting
92 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡